Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Cellcept (Labeling)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA supplemental approval for a labeling change to CellCept (mycophenolate mofetil) 250 mg capsules approved on 29 July 2026. The record documents a regulatory action only and does not contain clinical trial results, efficacy data, or comparative evidence.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory record, not a clinical study; no efficacy, safety, or comparative outcome data are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval action for labeling change; does not report clinical trial outcomes or comparative efficacy data.

Caveats

This is a regulatory record, not a clinical study; no efficacy, safety, or comparative outcome data are reported.
The specific nature and content of the labeling change are not detailed in the source.
No clinical trial results, sample sizes, or endpoints are provided.
The record does not support inferences about clinical benefit or comparative effectiveness.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no clinical study design reported.

Directness

insufficient

Labeling action only; no clinical outcome data provided.

Consistency

insufficient

Single regulatory action; no comparative or replication data.

Risk of bias

insufficient

Regulatory record does not address trial bias or methodology.

Sample adequacy

insufficient

No clinical data or sample size reported in labeling action.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA050722. This is a regulatory action record, not a clinical study. Brand name: CELLCEPT. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: ROCHE PALO. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-29. Products: CELLCEPT, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilRoche Palo